Lipella Pharmaceuticals (LIPO, Financial) has been granted U.S. Patent No. 12,326,492, which introduces innovative systems and techniques for identifying interstitial cystitis. This patent, officially issued by the United States Patent and Trademark Office on June 10, 2025, ensures protection until at least 2045, with possible extensions.
The technology described in the patent employs magnetic resonance imaging (MRI) to spot lesions in body cavities. This method holds the potential to significantly enhance outcome evaluations in Lipella's research endeavors, particularly in treating mucosal disorders. The company's current projects that could benefit from this advancement include LP-310 for oral lichen planus, LP-10 for hemorrhagic cystitis, and LP-50 for bladder cancer.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Lipella Pharmaceuticals Inc (LIPO, Financial) is $10.00 with a high estimate of $10.00 and a low estimate of $10.00. The average target implies an upside of 248.43% from the current price of $2.87. More detailed estimate data can be found on the Lipella Pharmaceuticals Inc (LIPO) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Lipella Pharmaceuticals Inc's (LIPO, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
